Drug
Revefenacin
Revefenacin: highest development phase Post-Market, developed by Theravance Biopharma, Viatris. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Theravance Biopharma, Viatris
Trials
| Drug | Phase | Indication |
|---|---|---|
| Revefenacin NCT05165485 | Post-Market | Chronic Obstructive Pulmonary Disease |
| Revefenacin NCT03573817 | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) |
| Revefenacin NCT03095456 | Phase 3 | Chronic Obstructive Pulmonary Disease, COPD |
Latest
No recent events.
Follow Revefenacin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.